Mentice (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, has announced the latest release of Ankyras® 5.0 in Europe. This enhanced version of the subscription-based clinical decision-support application, now classified as a Class IIb medical device, offers enhanced safety, reliability, and certification for use in complex, high-risk neurovascular cases. The application supports medical professionals select the most optimal flow diverters for treating intracranial aneurysms.

Managing complex intracranial aneurysms, particularly those with wide-neck configurations and irregular morphologies remains a significant challenge for interventional neuroradiologists. While traditional endovascular treatments, such as coiling face higher recurrence rates, reported between 20-50% within a year[1], while flow diversion, though promising for certain cases, carries risks such as ischemic complications due to stent thrombosis[2] and suitability issues for certain aneurysm types[3]. By providing data-driven insights, Ankyras® 5.0 addresses these complexities by offering advanced and improved treatment planning, supporting enhanced clinical decision-making and patient outcomes.
‍

Key Enhancements in Ankyras 5.0:

1. ‍New Intended Use and Risk Class (Class IIb Certification):The new classification reinforces Ankyras 5.0’s compliance with the highest safety and reliability standards for critical clinical applications, instilling confidence in healthcare professionals when utilizing the application for high-risk, high-cost procedures.  While this certification does not directly alter the user experience, it guarantees that Ankyras adheres to the highest regulatory standards, offering healthcare providers across Europe security and safety assurances in critical care treatment planning.
   ‍
2. Improved Image and Mesh Rendering: With improved image and mesh rendering quality, the update allows users to visualize vascular structures with greater clarity. This improvement ensures that vessel images appear more accurate and realistic, offering a clear advantage in procedural planning and decision-support for medical professionals.
   ‍
3. Enhanced Vessel Length Visualization: Users can now see the vessel length between neck and extension of flow diverter, offering a more comprehensive view compared to the previous version. This minor but impactful refinement helps medical providers get a more comprehensive view during the analysis of vascular structures, streamlining workflow.
   ‍
4. Circularity Chart: Ankyras 5.0 introduces a new chart displaying vessel circularity, providing additional insights for thorough vascular assessments. While this feature is in its early stages, it demonstrates our ongoing commitment to innovation and will be further refined in future updates.
   ‍
5. User Interface (UI) Simplification: The software has been refined for ease of use, removing unnecessary buttons for a more intuitive experience. These minor changes eflect our ongoing efforts to prioritize ease of use and efficiency within the clinical workflow for healthcare professionals.
   ‍

The Ankyras® decision-support application remains a valuable tool for medical professionals, providing precise, real-time decision support during neurovascular procedures. The application's ability to model complex interactions between blood vessels and flow diverters, considering parameters such as porosity, expansion, and foreshortening, ensures better treatment planning and improved patient outcomes.

‍

With enhanced image quality and user interface, Ankyras 5.0 offers healthcare professionals high accuracy and a more intuitive workflow, helping to streamline procedures and optimize device placement. Additionally, the Class IIb CE Mark certification reinforces Ankyras 5.0's reliability and compliance with European safety standards, making it a BSI-approved application for healthcare systems across the continent.

‍

For more information on Ankyras® 5.0 or to arrange a demo, visit www.mentice.com/Ankyras.

‍